Fatty liver disease and hypertransaminasemia hiding the association of clinically silent Duchenne muscular dystrophy and hereditary fructose intolerance
© Paolella et al.; licensee BioMed Central Ltd. 2012
Received: 1 October 2012
Accepted: 27 October 2012
Published: 31 October 2012
We report a case with the association of well self-compensated hereditary fructose intolerance and still poorly symptomatic Duchenne type muscular dystrophy. This case illustrates the problems of a correct diagnosis in sub-clinical patients presenting with “cryptogenic” hypertransaminasemia.
KeywordsHypertransaminasemia Fatty liver Hereditary fructose intolerance Muscular dystrophies
The epidemics of obesity at all ages is still relentless. The cause of an incidental and persistent finding of fatty liver and/or cryptogenic isolated mild hypertransaminasemia (HTS) in a child may therefore tend to be more and more undervalued and wrongly included within the spectrum of "non alcoholic fatty liver disease" (NAFLD).
Differential diagnosis with other more rare, and sometimes poorly known metabolic/genetic, conditions[2–6] in fact is imperative to avoid these patients not to profit of specific, possibly lifesaving, treatments. An exceedingly high index of suspicion is therefore required, also because multiple causes sharing identical pathological findings exist. Here we present a case of cryptic and well self-compensated hereditary fructose intolerance whose identification was triggered by the accidental finding of muscular hypertransaminasemia due to a still poorly manifest Duchenne type muscular dystrophy.
CS, a 3-year and 4-month old boy, was admitted to our teaching hospital for HTS. He was the full term, second-born of non-consanguineous parents. He pronounced his first words after the first year, and took autonomous first steps at 24 months. Sugar, sweets and fruit refusal was reported since early life.
The first occasional discovery of HTS at age 2 years (Alanine aminotransferase x 5 upper normal values (unv), Aspartate aminotransferase x 6 unv) was confirmed at 3 subsequent outpatient checks. At entry physical examination showed a well-cooperating boy, with a hypo-mimic face. Height, weight and head circumference were normal for age and gender. Abdomen was expanded and tense. Liver and spleen were palpable at 5 and 1 centimeters under the costal ridges, respectively. Liver consistency was reduced. Mild bilateral gastrocnemius pseudohypertrophy was noticed. Gower sign was positive with discrete weakness of legs antagonists, making impossible to climb the stairs without the help of the upper limbs, and use of supports for both the transition from sitting position to standing, and for walking (wide base, accentuation of the lumbar lordosis).
Abnormal biochemical laboratory investigation at entry
≤ 41 U/I
≤ 45 U/I
Lactic acid dehydrogenase
≤ 882 U/I
≤ 190 U/I
Echocardiogram and electrocardiography did not show any gross abnormalities.
The molecular analysis for dystrophinopathies showed the patient be hemizygous for the macrodeletion comprising exons 49–50 of the dystrophin gene, compatible with Duchenne/Becker Muscular Dystrophy. His mother was heterozygous for the same macro-deletion.
Due to the existence of the association fatty liver and sweet foods dislike/aversion, the molecular analysis for the hereditary fructose intolerance (HFI), was also performed. The patient eventually resulted heterozygous for mutations pA150P and pY204X (c.612T> A), respectively localized in exons 5 of the gene ALDOB. In order to confirm that the 2 mutations were present in trans (on two different alleles) the molecular analysis was performed also in the two parents. This showed a compatible genotype with heterozygous carrier status.
At hospital discharge, due to absence of evident muscle retraction (prevalence of hyposthenia), no need for immediate physiatric treatments was agreed. A fructose/sucrose/sorbitol free diet along with a list of allowed/forbidden drugs was prescribed.
Our case describes for the first time the association of hereditary fructose intolerance and Duchenne muscular dystrophy, and provides the opportunity of discussing the difficulties in the evaluation of the finding elevated transaminase levels in a still poorly symptomatic/asymptomatic patient. This may represent a significant diagnostic challenge for physicians, given the exceedingly wide range of possible infectious, autoimmune, metabolic, systemic, gastrointestinal causes of liver disease, and also of extrahepatic origin hypertransaminasemias. A detailed evaluation of the initial history, and a clinically oriented examination are crucial to assess the severity, and to determine the likely etiology/etiologies of hypertransaminasemia.
If hyperCKemia accompanies hypertransaminasemia it is mandatory to exclude muscular diseases, which are often clinically asymptomatic during the first 5–6 years of life and are frequently recognized only after a detailed and oriented neurologic examination. Duchenne muscular dystrophy (Phenotype MIM number 310200) is caused by mutation in the gene encoding dystrophin (DMD; 300377) with location on Xp21.2-p21.1. In a 12-year prospective study in the Campania region of southern Italy, Nigro et al. found an incidence of DMD of 21.7 per 100,000 male live births. In addition to the classical muscular dystrophies (dystrophinopathies), myocyte injury and necrosis induced by drugs or toxins, increased exercise, and some mitochondrial, endocrine and metabolic (e.g. storage diseases) myopathies, and gluten enteropathy are however possible additional causes of hyperCKemia and hypertransaminasemia, needing accurate exclusion according to age and clinical scenario[2, 11, 12]. The association between muscular dystrophy and obesity related NAFLD has been recently reported as well, and it emerges the need for a specific handling to avoid further muscular damage consequent to excessive caloric restriction or exercise. The associated condition presented by our patient, HFI (gene locus ALDOB, location 9q31.1, Phenotype Fructose intolerance, MIM number 229600) has an incidence of 1:20,000. In addition to occur with a possible typical presentation pattern of early-onset cholestasis during weaning, it may also present later on in patients who spontaneously follow a low fructose diet as a result of innate fructose dislike. In these cases, medical observation may be consequent to an incidental finding of hypertransaminasemia, and/or hepatomegaly and/or bright liver at ultrasound observation. The correct feeding history is crucial for the diagnosis, which may be confirmed by molecular analysis of the gene mutations as in our case. The association of these two rare diseases has never been previously reported: the different chromosomes involved and the parental carrier state suggest that it is a fortuitous event.
In conclusion our case emphasizes that when hypertransaminasemia and/or fatty liver are diagnosed one should nonetheless be alert to the possibility of overlooking a series of other, possibly treatable, coincidental causes of liver damage such as celiac disease[14, 15], Wilson disease, autoimmune hepatitis, several genetic rarer diseases[18–20] or even muscular diseases. Prompt recognition of some of these associated conditions may be crucial to avoid invasive tests[21, 22], and immediately start appropriate therapies[23, 24] that might dramatically change the natural history of the associated hidden cause of liver disease.
Written informed consent was obtained from the patient's family for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Hepatitis A virus
Hepatitis B core Antigen
Hepatitis B surface Antigen
Hepatitis C virus
Hereditary fructose intolerance
Non alcoholic fatty liver disease
Upper normal values.
- Cassiman D, Jaeken J: NASH may be trash. Gut. 2008, 57: 141-144. 10.1136/gut.2007.123240.View ArticlePubMedGoogle Scholar
- Vajro P, Veropalumbo C: Citrin deficiency: learn more, and don't forget to add it to the list of neonatal cholestasis and the NASH trash bin. J Pediatr Gastroenterol Nutr. 2010, 50: 578-579. 10.1097/MPG.0b013e3181dee0e3.View ArticlePubMedGoogle Scholar
- Casa RD, Ungaro C, Acampora E, Pignata C, Vajro P, Salerno M, Santamaria F, Parenti G: A case of galactosemia misdiagnosed as cow's milk intolerance. Ital J Pediatr. 2012, 38: 47-10.1186/1824-7288-38-47.PubMed CentralView ArticlePubMedGoogle Scholar
- Vajro P, Fontanella A, Tedesco M, Vecchione R, D'Armiento M: Fulminant hepatitis B and neonatal hepatitis with galactosemia-like presentation. Clin Pediatr (Phila). 1991, 30: 191-193. 10.1177/000992289103000311.View ArticleGoogle Scholar
- Mandato C, Brive L, Miura Y, Davis JA, Di Cosmo N, Lucariello S, Pagliardini S, Seo NS, Parenti G, Vecchione R, Freeze HH, Vajro P: Cryptogenic liver disease in four children: a novel congenital disorder of glycosylation. Pediatr Res. 2006, 59: 293-298. 10.1203/01.pdr.0000196378.30165.26.View ArticlePubMedGoogle Scholar
- Coppola G, Vajro P, De Virgiliis S, Ciccimarra E, Boccone L, Pascotto A: Cerebellar vermis defect, oligophrenia, congenital ataxia, and hepatic fibrocirrhosis without coloboma and renal abnormalities: report of three cases. Neuropediatrics. 2002, 33: 180-185. 10.1055/s-2002-34492.View ArticlePubMedGoogle Scholar
- Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, Durmaz O, Lacaille F, McLin V, Nobili V: Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012, 54: 700-713. 10.1097/MPG.0b013e318252a13f.View ArticlePubMedGoogle Scholar
- Vajro P, Di Cosmo N, Capuano G: Approach to the asymptomatic child with protracted hypertransaminasemia. Essential Pediatric Gastroenterology, Hepatology, & Nutrition. Edited by: Guandalini S. 2005, McGraw-Hill, New York, 335-344.Google Scholar
- Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD. MIM Number, #310200: 8/5/2012. World Wide Web URL:http://omim.org/,
- Nigro G, Comi LI, Limongelli FM, Giugliano MAM, Politano L, Petretta V, Passamano L, Stefanelli S: Prospective study of X-linked progressive muscular dystrophy in Campania. Muscle Nerve. 1983, 6: 253-262. 10.1002/mus.880060403.View ArticlePubMedGoogle Scholar
- Vajro P, Del Giudice E, Veropalumbo C: Muscular dystrophy revealed by incidentally discovered elevated aminotransferase levels. J Pediatr. 2010, 156: 689-View ArticlePubMedGoogle Scholar
- Veropalumbo C, Del Giudice E, Capuano G, Gentile C, Di Cosmo N, Vajro P: Duchenne and Becker muscular dystrophy presenting as nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2011, 53: 463-464. 10.1097/MPG.0b013e318217f5d9.View ArticlePubMedGoogle Scholar
- Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD, MIM Number: #229600: 3/16/2011. World Wide Webhttp://omim.org,
- Franzese A, Iannucci MP, Valerio G, Ciccimarra E, Spaziano M, Mandato C, Vajro P: Atypical celiac disease presenting as obesity-related liver dysfunction. J Pediatr Gastroenterol Nutr. 2001, 33: 329-332. 10.1097/00005176-200109000-00019.View ArticlePubMedGoogle Scholar
- Vajro P, Paolella G, Pisano P, Maggiore G: Hypertransaminasemia and coeliac disease. Aliment Pharmacol Ther. 2012, 35: 202-203. 10.1111/j.1365-2036.2011.04895.x. author reply 203–4View ArticlePubMedGoogle Scholar
- Iorio R, D'Ambrosi M, Marcellini M, Barbera C, Maggiore G, Zancan L, Giacchino R, Vajro P, Marazzi MG, Francavilla R, Michielutti F, Resti M, Frediani T, Pastore M, Mazzarella G, Fusco G, Cirillo F, Vegnente A: Hepatology Committee of Italian Society of Paediatric Gastroenterology Hepatology and Nutrition. Serum transaminases in children with Wilson's disease. J Pediatr Gastroenterol Nutr. 2004, 39: 331-336. 10.1097/00005176-200410000-00006.View ArticlePubMedGoogle Scholar
- Vajro P, Paolella G: Autoimmune hepatitis: current knowledge. Clin Res Hepatol Gastroenterol. 2012, 36: 284-286. 10.1016/j.clinre.2012.03.023.View ArticlePubMedGoogle Scholar
- Colombo C, Vajro P, Degiorgio D, Coviello DA, Costantino L, Tornillo L, Motta V, Consonni D, Maggiore G: SIGENP Study Group for Genetic Cholestasis. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr. 2011, 52: 73-83. 10.1097/MPG.0b013e3181f50363.View ArticlePubMedGoogle Scholar
- Gentile M, Di Carlo A, Susca F, Gambotto A, Caruso ML, Panella C, Vajro P, Guanti G: COACH syndrome: report of two brothers with congenital hepatic fibrosis, cerebellar vermis hypoplasia, oligophrenia, ataxia, and mental retardation. Am J MedGenet. 1996, 64: 514-520.View ArticleGoogle Scholar
- Rossi M, Vajro P, Iorio R, Battagliese A, Brunetti-Pierri N, Corso G, Di Rocco M, Ferrari P, Rivasi F, Vecchione R, Andria G, Parenti G: Characterization of liver involvement in defects of cholesterol biosynthesis: long-term follow-up and review. Am J Med Genet A. 2005, 132A: 144-151. 10.1002/ajmg.a.30426.View ArticlePubMedGoogle Scholar
- Lee M, Vajro P, Keeffe EB: Isolated aspartate aminotransferase elevation: think macro-AST. Dig Dis Sci. 2011, 56: 311-313. 10.1007/s10620-011-1575-4.View ArticlePubMedGoogle Scholar
- Caropreso M, Fortunato G, Lenta S, Palmieri D, Esposito M, Vitale DF, Lorio R, Vajro P: Prevalence and long-term course of macro-aspartate aminotransferase in children. J Pediatr. 2009, 15: 744-748.View ArticleGoogle Scholar
- Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H: Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr. 2009, 48: 587-596. 10.1097/MPG.0b013e31818e04d1.View ArticlePubMedGoogle Scholar
- Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R: Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011, 52: 740-743. 10.1097/MPG.0b013e31821f9b85.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.